Enovis Corporation $ENOV Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. lifted its stake in shares of Enovis Corporation (NYSE:ENOV) by 2.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 6,524,235 shares of the company’s stock after purchasing an additional 125,460 shares during the quarter. Vanguard Group Inc. owned about 0.11% of Enovis worth $197,945,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Capital Fund Management S.A. purchased a new stake in shares of Enovis during the 2nd quarter worth approximately $1,682,000. Assenagon Asset Management S.A. purchased a new position in Enovis in the 3rd quarter valued at approximately $4,045,000. Impax Asset Management Group plc raised its holdings in Enovis by 47.5% during the third quarter. Impax Asset Management Group plc now owns 310,630 shares of the company’s stock worth $9,425,000 after purchasing an additional 100,000 shares during the last quarter. Osaic Holdings Inc. raised its holdings in Enovis by 56.0% during the second quarter. Osaic Holdings Inc. now owns 139,727 shares of the company’s stock worth $4,382,000 after purchasing an additional 50,156 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in Enovis by 32.4% during the second quarter. Rhumbline Advisers now owns 172,341 shares of the company’s stock worth $5,405,000 after purchasing an additional 42,138 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Insiders Place Their Bets

In other Enovis news, EVP Daniel A. Pryor sold 999 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total value of $27,172.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 2.70% of the company’s stock.

Enovis Stock Up 0.3%

ENOV stock opened at $25.49 on Monday. The stock has a market capitalization of $1.46 billion, a P/E ratio of -1.23 and a beta of 1.46. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.02. Enovis Corporation has a one year low of $21.00 and a one year high of $40.69. The company has a 50 day moving average price of $24.27 and a two-hundred day moving average price of $28.18.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The company had revenue of $575.76 million for the quarter, compared to analyst estimates of $584.30 million. During the same quarter in the prior year, the company posted $0.98 EPS. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, sell-side analysts expect that Enovis Corporation will post 2.79 EPS for the current year.

More Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Adjusted EPS beat — Enovis reported adjusted EPS $0.95 versus consensus ~$0.81, signaling underlying profitability on a non‑GAAP basis. Enovis Q4 2025 Earnings Call Highlights
• Positive Sentiment: Management raised FY2026 adjusted EPS guidance to $3.52–$3.73 (above consensus ~3.35) and expects adjusted EBITDA expansion, providing a clearer path to earnings recovery. Enovis targets $2.31–$2.37B 2026 revenue
• Positive Sentiment: Operational momentum — full‑year 2025 net sales grew ~7% (6% organic) with Reconstructive up ~10% Y/Y; adjusted EBITDA and adjusted EPS for the year improved on a non‑GAAP basis. Enovis Announces Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Analyst activity supportive — BTIG raised its price target to $43 and keeps a buy stance, signaling some sell‑side confidence in the recovery story. BTIG price target raise
• Neutral Sentiment: Guidance mix — revenue guidance of $2.31–$2.37B implies 4–6% organic growth (positive), but the top‑end sits below some street expectations — a watch item for revenue‑sensitive investors. Guidance detail
• Negative Sentiment: Revenue miss and GAAP impairment — Q4 revenue ~$575.8M missed consensus (~$584M) and the company took a $501M non‑cash goodwill impairment (Q4) that produced a large GAAP loss (Q4 net loss from continuing operations ~$519M), raising concerns about past acquisition valuation and near‑term GAAP volatility. Enovis Misses Q4 Sales Expectations
• Negative Sentiment: Significant non‑cash charges dent headline results — investors focused on GAAP losses and goodwill write‑downs may remain cautious despite positive adjusted metrics. Quiver/summary of results and impairment

Wall Street Analysts Forecast Growth

ENOV has been the subject of a number of research analyst reports. Evercore restated an “outperform” rating on shares of Enovis in a research report on Monday, January 12th. Canaccord Genuity Group dropped their target price on shares of Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, December 17th. UBS Group restated a “buy” rating and set a $50.00 target price on shares of Enovis in a research report on Monday, January 5th. Needham & Company LLC raised their price objective on shares of Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, BTIG Research upped their target price on Enovis from $41.00 to $43.00 and gave the company a “buy” rating in a research note on Thursday. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $47.43.

Enovis Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.